When the Government Calls Your Procedures Into Question: The OIG Report on Office-Based Vascular Care

By Elina Sabilova, CPC, CFPC, CPMA, Billing Department, WCH

The Setup

In early May 2026, the HHS Office of Inspector General published a report that sent a quiet but unmistakable signal to the vascular care community: the federal government has been watching, and it doesn’t like what it sees. The report, titled “Utilization Trends and Medicare Part B Billing for Office-Based Peripheral Vascular Procedures Raise Questions About Program Integrity,” is not a list of indictments. It contains no names. It makes no formal accusations. But its findings are pointed enough — and its language deliberate enough — that anyone practicing office-based vascular interventions in the United States should read it carefully.

The short version: Medicare Part B paid over $1 billion in 2022 for peripheral vascular procedures — angioplasty, stenting, and atherectomy — intended to relieve leg pain caused by arterial narrowing or blockage. For years, interest holders have raised concerns about potential overuse of these procedures when professional guidelines recommend that conservative treatments, such as medication and lifestyle changes, be tried first. Medicare Part B payments to physicians are higher when they perform these procedures in office-based laboratories compared to other settings. The OIG went looking for abuse of that payment differential — and found evidence consistent with it at significant scale.

What the Report Actually Found

Overall, Medicare paid physicians approximately $548 million for performing peripheral vascular procedures in an office-based laboratory (OBL) setting in 2023. Looking closer at these cases, the OIG believes approximately 19% — $105 million — of those procedures may have been medically unnecessary. These potentially problematic payments went to a total of 139 physicians — 7% of the total pool — representing the fields of vascular surgery, cardiology, interventional cardiology, and interventional radiology.

The concentration of the problem is striking. About 26 physicians were responsible for the majority of the flagged payments — each receiving about $3 million in Medicare payments on average — and they treated more than four times the average number of Medicare patients compared with similar physicians, conducting double the average number of procedures per patient. About half of these flagged doctors, including interventional radiologists, vascular surgeons, and cardiologists, practiced in California and Texas.

The OIG also flagged two specific procedure types as particularly concerning. Despite routine use of atherectomy and tibial artery procedures being controversial due to potential complication risks and poor outcomes, physicians used these procedures often in OBLs — 75% and 47% of procedures, respectively.

The OIG’s recommendations to CMS were direct: monitor billing to identify peripheral vascular procedures that may be medically unnecessary, and follow up on the physicians identified with concerning billing patterns. CMS concurred with both recommendations.

Why This Is Bigger Than 139 Physicians

It would be comfortable to read this report as a narrowly scoped enforcement signal aimed at a small number of bad actors. That reading is probably wrong, for several reasons.

First, the denominator matters. The OIG flagged 7% of OBL-based vascular physicians as having concerning billing. But the methodology was conservative — the 139 physicians were identified through statistical outlier analysis, not clinical record review. The report explicitly notes that determining whether any specific physician engaged in fraudulent or abusive practices was outside its scope. That means the 139 are the statistical tail, not a comprehensive census of problematic billing. The actual prevalence of unnecessary procedures across the full population of OBL vascular providers is likely higher — and the OIG knows it.

Second, the structural incentive that drives the problem hasn’t been addressed. The payment differential between OBL settings and hospital outpatient departments is large, well-documented, and has been the subject of policy concern for years. For calendar years 2022 and 2023 combined, Medicare paid approximately $1.16 billion for lower extremity peripheral vascular procedures in office settings. That is a payment stream large enough to reshape practice patterns — and in some cases, it demonstrably has. The OIG report does not recommend eliminating or restructuring the OBL payment differential. It recommends monitoring. That is a measured response, but it leaves the underlying incentive architecture intact.

Third, the clinical stakes are not abstract. The OIG’s concerns are not primarily financial. Overuse of these procedures may lead to Medicare paying for medically unnecessary services, but it also creates direct risks for patients, such as amputation. This is not a billing irregularity story — it is a patient safety story with a billing irregularity component. Atherectomy, in particular, has a risk profile that makes unnecessary use genuinely dangerous, and the OIG report’s finding that 75% of OBL atherectomies were performed in a context of controversial clinical utility is a serious finding, not a bookkeeping anomaly.

The ProPublica Thread

The OIG report did not emerge in a vacuum. The analysis parallels a 2023 ProPublica investigation that revealed how high Medicare reimbursements for office-based vascular treatments had fueled a surge of unnecessary procedures, putting patients at risk of amputation or even death. The OIG study, which began in April 2024, cited the ProPublica report and broadly corroborated its findings.

That the inspector general’s formal analysis confirms a journalism investigation published three years earlier is itself significant. It suggests the problem was visible, identifiable, and broadly understood within the healthcare oversight community well before any formal action was taken. The lag between recognition and response — from the 2023 ProPublica reporting to the May 2026 OIG report — reflects both the deliberate pace of federal health oversight and, more critically, the amount of harm that can accumulate during that interval.

Since 2019, CMS has investigated and identified 15 healthcare providers that received overpayments for vascular procedures. The agency also launched a Billing Analysis Project to detect physicians who are excessively billing for certain procedures, including atherectomies. Fifteen cases in seven years, against a backdrop of $105 million in potentially unnecessary procedures in a single year, suggests enforcement has not kept pace with the problem.

The Medical Societies’ Response

The cardiovascular and vascular specialty societies were not silent. SCAI, the Association of Black Cardiologists, the Society of Interventional Radiology, the Society for Vascular Surgeons, and the Outpatient Endovascular and Interventional Society released a joint statement saying: “We share OIG’s commitment to the appropriate use of Medicare resources and to ensuring that patients with PAD receive care that is both medically necessary and consistent with established clinical evidence.”

The statement is diplomatically worded, and that diplomacy is appropriate — these societies are speaking for their entire membership, the vast majority of whom are not among the 139 flagged physicians. But the joint statement also performs an important function: by publicly aligning with OIG’s stated goals, the societies implicitly acknowledge that the problem described in the report is real, and they signal to their own members that the specialty’s leadership will not reflexively defend high-volume OBL billing as a protected clinical prerogative.

The OIG was careful in its language: “Although determining whether these physicians engaged in abusive or fraudulent practices was not within the scope of this study, their billing patterns warrant further scrutiny.” That formulation — “warrant further scrutiny” — is as close to a warning shot as federal oversight language gets without an actual referral to the Department of Justice.

The Office-Based Laboratory Model Under Pressure

The OBL model — physician-owned outpatient facilities where vascular and interventional procedures can be performed and billed at rates higher than a hospital outpatient clinic — has been one of the growth stories in cardiovascular and vascular medicine over the past decade. The appeal is real: lower overhead than hospitals, faster scheduling, more physician control over the care environment, and in genuinely appropriate cases, better patient convenience.

The appeal is also financial. The OBL setting generates higher Medicare reimbursement per procedure than other settings, and in a specialty where procedure volume drives revenue, that differential creates a powerful incentive. The OIG report is, at its core, a finding that for a meaningful subset of practitioners, that financial incentive has overridden clinical judgment about when procedures are warranted.

What happens next will depend on whether CMS follows through on both of OIG’s recommendations — particularly the second one, which requires actual follow-up on the 139 identified physicians. Prior enforcement history, as noted above, suggests the follow-through has been inconsistent. But the political environment in 2026, with the Trump administration publicly committed to reducing healthcare waste and fraud, may accelerate action. The OIG report gives CMS the documented basis it needs to pursue overpayment recovery and, in the most egregious cases, exclusion proceedings.

What Physicians and Health Systems Should Take From This

For vascular surgeons, interventional cardiologists, and interventional radiologists practicing in the OBL setting, this report warrants a systematic self-assessment of procedure appropriateness documentation. The OIG’s methodology for identifying concerning billing patterns was statistical — high procedure volume, high per-patient procedure rates, high use of controversial procedures. Those are the signals that will trigger enhanced scrutiny. Physicians whose practice patterns generate those signals need to ensure their clinical documentation thoroughly supports medical necessity for each case.

For health systems and integrated practice groups that employ or contract with OBL-based vascular specialists, the report is a compliance alert. If employed physicians’ OBL billing patterns fall within the statistical range flagged by OIG, the institution has a shared exposure — and a shared responsibility to investigate.

For policymakers, the report raises a question that monitoring alone cannot answer: whether the OBL payment differential that created this incentive structure should be recalibrated. The OIG’s scope was limited to fraud, waste, and abuse analysis, not payment policy design. But the two are not separable. A payment architecture that systematically over-incentivizes high-volume procedure use in physician-owned facilities will continue to generate these patterns regardless of how aggressively enforcement is applied at the margins.

***

The May 2026 OIG report on office-based peripheral vascular procedures is an important document that deserves more attention than it has received. It is not sensational — it names no names, makes no charges, and reaches measured conclusions. But beneath that careful language is a finding with real weight: roughly one-fifth of Medicare spending on OBL vascular procedures in 2023 may represent medically unnecessary care, concentrated in a small number of practitioners whose billing patterns are statistically anomalous and whose patients appear to be receiving procedures at rates inconsistent with clinical guidelines. That is not a rounding error. That is a systemic problem — one that affects program integrity, consumes public resources, and in the worst cases, harms the patients it purports to treat.

The specialty societies are right to align publicly with OIG’s goals. The question now is whether that alignment translates into concrete action at the practice level — and whether CMS follows through on the targeted scrutiny the OIG has recommended.

Questions about how this report could affect your practice? Contact the WCH team. Our compliance and billing specialists can help you assess procedural documentation, evaluate billing patterns, and prepare for increased scrutiny of office-based vascular services. https://wchsb.com/contact-form/

Sources

1. HHS OIG Report: “Utilization Trends and Medicare Part B Billing for Office-Based Peripheral Vascular Procedures Raise Questions About Program Integrity,” May 5, 2026. oig.hhs.gov (Report No. OEI-01-24-00250)
2. Cardiovascular Business: “Trump administration questions vascular care provided by surgeons, cardiologists and radiologists,” June 1, 2026. cardiovascularbusiness.com
3. Cardiovascular Business: “Medical societies respond after Trump administration questioned necessity of certain procedures,” June 2, 2026. cardiovascularbusiness.com
4. ProPublica: “More Than $100 Million Was Billed for Medically Questionable Vascular Procedures, Government Watchdog Finds,” May 29, 2026. propublica.org
5. HHS OIG Work Plan Summary: “Utilization of Peripheral Vascular Procedures and CMS’s Related Program Integrity Efforts,” initiated April 2024. oig.hhs.gov
6. HHS OIG Work Plan Summary: “Medicare Payments for Lower Extremity Peripheral Vascular Procedures,” initiated June 2024. oig.hhs.gov